HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and raises the price target from $40 to $43.

March 01, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akero Therapeutics' Buy rating is maintained by HC Wainwright & Co., with an increased price target from $40 to $43.
The maintenance of a Buy rating combined with an increased price target typically signals a positive outlook on the stock by the analyst, suggesting a belief in the company's future performance and potential for stock price appreciation. This can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100